Pengaruh Polimorfisme Gen Beta Fibrinogen-455 G ke A Pada Pemberian Aspirin Dan Efeknya Terhadap Skor Barthel Indeks Dan Modified Rankin Scale Penderita Stroke Iskemik Berdasarkan Kelompok Usia

  th

  Adams,R.D., Victor, M., and Ropper, A.H. 2001. Principle of Neurology, 7 ed. Mc.Graw-Hill. New York. Agustini,S., Khairani, A., Sitorus,F. 2010. Gambaran Stroke Pada Wanita di RSUPN Cipto Mangunkusumo. Dalam: Majalah Neurona.

  Perhimpunan Dokter Spesialis Saraf Indonesia. Jakarta. Hal:30-34. Ahmed, S.H., Hu, C.J., Paczynski, R., Hsu, C.Y. 2001. Pathophysiology of

  nd

  ischemic injury. In: Fischer,M. editor. Stroke Therapy. 2 ed. Boston Butterworth- Heinemann.p. 25 – 49. Ajjan. R.A., Standeven, K.F., Khanbhai,M., Phoenix,K.C., Gersch,J.W.,

  Weisel,M.T. et al. 2009. Effects of Aspirin on Clot Structure and Fibrinolysis using a Novel in vitro cellular system. Arteriosclerosis, Thrombosis and Vascular Biology.2009.29:712-717.

  Albala,B.B., Sacco,R.L. 2002. Modifiable risk factor for stroke: hypertension, diabetes mellitus, lipids, tobacco use, physical inactivuty, and alcohol. In: Gorelick, P.B., Alter, M., editors. The Prevention of Stroke. Boca Raton: The Parthenon Publishing Group.p. 21-37. Altman, R., Luciardi, H.L., Muntaner, J., Herrera, R.N. 2004. The antithrombotic profile of aspirin. Aspirin resistence or simply failure.BioMed Thrombosis Journal.2: 1-8. Ananyeva N.M., Kouiavskaia D.V., Shima M., and Saenko E.L.2002.

  Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque. Blood.,99:4475-4485. Antithrombotic Trialists Collaboration, 2002. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ.324:71-86. Aono, Y., Ohkubo, T., Kikuya, M.,Hara, A., Kondo, T., Obara.,T. et al.

  2007. Plasma Fibrinogen, Ambolatory Blood Pressure, and Silent Cerebrovascular Lesion: The Ohasama Study. Arterioscler Thromb Vasc Biol. 27 : 963-968.

Blake, G.J., Schmidtz,C., Lindpaintner, K., Ridker,P.M. 2001. Mutation in the promoter region of the β-fibrinogen gene and the risk of future

  myocardial infarction, stroke and venous thrombosis. European Heart Journal. 22:2262-2266.

  153 Blann, A.D., Landray, M.J., Lip, G.Y.H. 2003. An of overview of antithrombotic therapy. In: Lip, G.Y.H, Blan, A.D. ABC of Antithrombotic therapy. BMJ Publishing Groups. Spain. p.10-13. Bogousslavsky, J., Paciaroni, M., Agnelli, G., Caso, V. 2012.

  Manifestasions of Stroke. Karger. Switzerland. Borissoff, J.I., Henri, M.H., Cate, H. 2011. The Hemostatic System as a Modulator of Atherosclerosis. The New England Journal of Medicine.

  364: 1746-60. Bielak LF, Klee GG, Sheedy PF, Turner ST, Schwartz RS, Peyser PA.

  2000 Association of Fibrinogen With Quantity of Coronary Artery Calcification Measured by Electron Beam Computed Tomography.

  Arterioscler Thromb Vasc Biol.20:2167-2171.

  Brummel-Ziedins K, Orfeo T, Jenny NS, Everse SJ, Mann KG. 2004.Blood Coagulation and Fibrinolysis in Wintrobe’s Clinical Hematology, ed.

  11, Chapt 21, Philadelphia: Lippincott Williams & Wilkins.

  rd Caplan, L.R. 2000. Caplan’s stroke: A clinical Approach. 3 ed.

  Butterworth-heinemann. Boston. Chao, C.X., Tong, X.U., Wu,Z., Li, H., Qing, C.W. 2007. A meta-analysis of relationship between beta fibrinogen gene -148 C/T polymorphism and susceptibility to cerebral infarction in Han Chinese. Chin. Med. J. 120(13):1198-1202. Chen,X.C., Xu, M.Y., Zhou, W., Han, C.L., Chen, W.Q. 2007. A meta analysis of beta fibrinogen gene -455 G/A polymorphism and plasma fibrinogen level in chinese cerebral infraction patients. Biomed environ Sci, 20(5): 366-72.

  Chuang, S.Y., Bai, C.H., Chen, W.H., Lien, L.M., Pan, W.H. 2009.

  Fibrinogen Independently Predicts the Development of Ischemic Stroke in a Taiwanese Population. CVDFACTS Study. Stroke.40: 1578-1584.

  Cook, N.S., Ubben, D. 1990. Fibrinogen as a major cardiovascular risk factor in cardiovascular disease. Trends Pharmacol Sci.11: 444-451. Connor, J.M., Fowkes, F.G., Wood J, Smith, F.B., Donnan, P.T., Lowe,

  G.D. 1992. Genetic variation at fibrinogen loci and plasma fibrinogen levels. J Med Genet , 29:480–482. Corte, A.L.C.L, Philippou, H., Ariens, R.A.S. 2011. Role of fibrin structure in thrombosis and vascular disease. Adv Protein Chemistry and

  Structural Biology.83:75-127. Coull, B.M., Beamer,N., Garmo,P.,Sexton, G.,Nordt,F., Knox,R. et. al.

  1991. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke. 22:162- 168 . Davi, G, Patrono, C. 2007. Platelet Activation and Atherothrombosis. The New England Journal of Medicine.357: 2482-94.

  Davis, S.M., Donnan, G.A. 2012. Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack. The New England Journal of Medicine. 166: 1914-22.

  Del Zoppo, G.J, Waren D.L, Wasieswki, W.W., Pancioli, A.M., Demchuck, A.M., Trammel, J.,et al. 2009. Hiperfibrinogenemia andFunctional outcome from Acute Ischemic Stroke. Stroke; 40: 1687-1691.

  Dewoto, H.R. 2007. Antikoagulan, antithrombotik. Trombolitik dan Hemostatik. Dalam: Gunawan, S.G., Setiabudy,R., Nafrialdi, Elysabeth. (Editor). Farmakologi dan Terapi. Departemen Farmakologi dan Terapeutik Fakultas Kedokteran- Universitas Indonesia. Balai Penerbit FK-UI, Jakarta. Hal. 813 – 814.

  Dienner, H.C.2006. Update on Clopidogrel and dual anti-platelet therapy: neurology. European Heart Journal Supplements G, G15-G19. DiCarlo, A., Lamassa, M., Baldereschi, M., Pracuci ,G., Basile, A.M.,

  Wolfe, C.D., et al. 2003. Sex differences in the clinical presentation, Resources use, and 3 month outcome of Acute stroke in Europe; data from a multicenter multinational hospital-based registry. Stroke.

  34 : 1114-1119. DiMinno G, Silver MJ, Cerbone AM, Rainone A, Postiglione A, Mancini M.

  1986 Increased Fibrinogen Binding to Platelets from Patients with Familial Hypercholesterolemia. Arteriosclerosis;6:203-211. Di Napoli, M., Elkind, M.S., Godoy, D.A., Sigh, P., Papa, F., Popa wagner, A. 2011. Role of C reactive Protein in Cerebrovascular Disease.

  Expert Rev Cardiovasc Ther.9: 1565-1584. Departemen Neurologi, R.S.U.P. Haji Adam Malik. 2011. Data penderita rawat inap tahun 2011.

  Debette. S., Seshadari,S. 2009. Genetics of Atherothrombotic and Lacunar Stroke. Circ. Cardiovasc. Genet.2: 191-198.

  El-Tarras,A.E., Awad, N.S., Said,M.M., Mitwaly,M. 2012. Detection of FXIII gene V34L and fibrinogen  gene -455 G/A polymorphisms among

  Saudi Arabia population via polymerase chain reaction-reverse hybridization technique. African Journal Biotechnology.11(80): 14536-145411. Ernst E, Matrai A, Scholzl C, Magyarosy I. 1987. Dose-effect relationship between smoking and blood rheology. Br J Haematol.,65: 485-7.

  Ernst E, Matrai A, Marshall M. 1988. Blood rheology in patients with transient ischemic attacks. Stroke.19:634-6. Ernst E, Koenig W, Matrai A, Filipiak B, Stieber J. 1988. Blood rheology in healthy cigarette smokers. Results from the MONICA Project,

  Augsburg. Arteriosclerosis. 8:385-8. Ernst, E., Resch, K.L.,1993. Fibrinogen as cardiovascular risk factor: a meta analysis and review of the literature. Ann Intern Med,118:956-

  963. Escobar, C.E., Harmening, D.M., Maier, D.M., Simmons, V.L., Smith-

  Moore, K.M., Wyrick-Glatzel,J.2002. Introduction to Hemostasis. In: Harmening, D.M. editors. Clinical Hematology and Fundamentals of

  th

  Hemostasis. 4 edition. F.A. Davis Company. Philadelphia. p. 441- 468. Fatchiyah, Arumingtyas, E.L., Widyarti, S., Rahayu, S. 2011. Biologi Molekuler. Prinsip Dasar Analisis. Penerbit Erlangga. Feher, M.D., Rampling, M.W., Brown, J., Robinson, R., Richmond,

  W.,Cholerton, S., Bain, B.J., Sever, P.S.1990. Acute changes in atherogenic and thrombogenic factors with cessation of smoking. J. Royal Socci Med. 83: 146-148. Ferdinand,M., Van ‘t Hooft, Sara,J.F., Von Bahr., Angela Silveira.,

  Abnastasia Iliadou.et al. 1999. Two common, Functional Polymorphisms in the Promoter Region of the β-fibrinogen gene Contribute to Regulation of Plasma Fibrinogen Concentration.

  Arteriosclerosis, Thrombosis and Vascular Biology.19:3063-3070. Feinberg WM, Erickson LP, Bruck D, Kittelson J. 1996. Hemostatic Markers in Acute Ischemic Stroke. Stroke. 27:1296-1300.

  Fergusson J.J. 2000. The Physiology of Normal Platelet Function.

  In:Fergusson J.J., Chronos N., Harrington, R.A eds. Antiplatelet Therapy in Clinical Practice. London. Martin Dunitz.p. 15-35.

  nd Fisher, M. 2001. Stroke Therapy,2 ed. Buttherworth-Heinemann. Freeman,M.S., Mansfield,M.W., Barret,J.H., Grant, P.J. 2002. Genetic Controbution to Circulating Levels of Hemostatic Factors in Healthy Families with effects of known Genetic Polymorphisms on Heritability. Arterioscl Thromb Vasc Biol.22:506-510.

  Furrie, B., Furrie,B.C. 2008. Mechanisms of Thrombus Formation. The New England Journal of Medicine.359: 938-49. Guideline Stroke.2011 . Pokdi Stroke. Perhimpunan Dokter Spesialis Saraf Indonesia (PERDOSSI). Jakarta. Glass, S.K., Witztum, J.L. 2001. Atherosclerosis. The road Ahead cell.

  Springer-Wien. New York. Goodman, T., Ferro,A., Sharma, P. 2008. Pharmacogenetics of aspirin resistence: a comprehensiv systematic review. British J Clin

  Pharmacol. 66(2): 222-232. Goldstein, L.B., 2006. Guidelines for the Primary Prevention of Ischemic

  Stroke: A Guidelines From The American Heart Association/ American Stroke Association Stroke.37:1583-1633. Gorman, M. 2000. Development and the rights of older people. In :

  Randal, J.eds. The ageing and development report: poverty, independence and the world’s older people. London. Earthscan Publication Ltd.p.3-21. Griendling,K.K., Sorescu,D., Fukai, M.U. 2000. NAD(P)H oxidase. Role in Cardiovascular Biology and Disease. Cir. Res. 86: 494–501.

  Hacke,W., Kaste, M, Bogousslavsky, J., Brainin, M., Gugging, M., Chamorro, A., Less,K., Leys, D., Kwiecinski, H., Toni, D. 2003.

  European Stroke Initiative: Ischemic Stroke Prophylaxis and Treatment. EUSI. Heidelberg. Hall, R., Mazel, C.D. 2011. Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period.

  Anethesia Analgesia.112: 293-318. Hankey, G.J., Hacke, W., Easton, D., Johnston, S.E., Mas, J.L. 2010.

  Effect of Clopidogrel on the Rate and Functional Severity Stroke Among High Vascular Risk Patients. Stroke.41: 1679-1683. Hansen, A.T., Larsen, B.A., Humphries, S.E., Abildgaard, S., Schnohr, P.,

  Nordestgaard, B.G. 1997. A Common mutation (G-455 A) in the  Fibrinogen Promoter is an independent predictor of Plasma Fibrinogen, but not of Ischemic Heart Disease. J. Clin. Invest,99: 3034-3039. Hamsten A, Iselius L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987; 2:988–

  91. Harmening, D.M. 2002. Clinical Hematology and Fundamentals of

  th Hemostasis. 4 eds.F.A. Davis Company, Philadelphia.

  Hills, N.K., Johnston, S.C. 2008. Trends in usage of alternative Antiplatelet Therapy after Stroke and Transicient Ischemic Attack. Stroke. 39: 1228-1232.

  Hoffbrand,A.V., Pettit, J.E., Moss, P.A.H. 2002. Kapita selekta hematologi.

  EGC. Jakarta. Hsieh, Y.C., Seshadri, S., Chung, W.T., Hsieh, F.I., Lin, H.J., Tseng, H.P. et al. 2012. Association between genetic variant on chromosome 12p13 and stroke survival and reccurence: one year prospective study in Taiwan. Journal of Biomedical Scence,19:1-8.

  Humphries SE, Cook M, Dubowitz M, Stirling Y, 1987. Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet,1:1452-5. Husted S. 2007. New Developments in oral antiplatelet therapy. European Heart Journal. Suplements.9: D20-D27.

  Iacoviello L., Vischetti M., Zito F., Donati M.B. 2001. Genes encoding Fibrinogen and Cardiovascular Risk. Hypertension. 38: 1199-1203. Ikram, M.A., Seshadri, S., Joshua, C.B., Fornage,M., DeStefano, A.L.,

  Aulchenko, Y.S. et al. 2009. Genom wide Association Studies of Stroke. N.Engl. J. Med.360: 1718 – 28. Ito U, Kuroiwa T, Nagasao J, Kawakami E, Oyanagi K.2006. Temporal

  Profiles of Axon Terminals, Synapses and Spines in the Ischemic Penumbra of the Cerebral Cortex Ultrastructure of Neuronal Remodeling. Stroke.37:2134-2139.

  Jennifer Mc Dowell. 2006. Fibrinogen. Protein Data Bank.

  

( http://www.ebi.ac.uk/interpro/potm/2006_11/Page1.htm) accessed

on oktober 18, 2012.

  Jumraini, 2012. Polimorfisme gen beta fibrinogen C148T dan hubungannya dengan kadar fibrinogen plasma pada populasi penderita stroke iskemik. Departemen Neurologi Fakultas Kedokteran Universitas Hasanuddin, Makasar (Disertasi).

  Johnston,K.C., Wagner,D.P., Haley,C., Connors,J. 2002. Combined Clinical and Imaging Informations as an early Stroke outcome measure. Stroke.33:466-472.

  Kamath S, Lip Gyh. 2003 .Fibrinogen; biochemistry, epidemiology and determinants, QJ Med ;96:711-729. Katzung,B.G., Trevor, A.J., Masters, S.B. 2005. Katzung and Trevor’s

  Pharmacology, Examination and Board Review. 7th ed. Mc-Graw Hill. Boston. Kavurma, M.M., Tan, N.Y., Bennet, M.R. 2008. Death Receptors and Their

  Ligands in Artheriosclerosis. Arterioscler Thromb Vasc Biol. 28: 1694-1702. Kelompok Studi Serebrovaskuler dan Neurogeriatri Perdossi. 1999.

  Konsensus Nasional Pengelolaan Stroke di Indonesi. Perdossi Jakarta. Kelompok Studi Stroke. 2007. Guideline Stroke. Perdossi. Jakarta. Kessler, C., Spitzer,C., Stauske,D., Mende, S., Stadlmuller, J., Walther, R.

  Et al. 1997. The Apolipoprotein E and β fibrinogen G/A -455 gene plymorphism are associated with ischemic stroke involving large vessel disease. Arteriosclerosis, Thrombosis, and Vascular Biology.17: 2880-2884.

  Kita,Y., Okayama, A., Ueshima, H., Wada, M., Nozaki, A. Chondhury, S.R.

  Bonita, R., Inamoto, Y., Kasamatsu, T. 1999. Stroke Incidence and Case Fatality in Shiga, Japan. International J of Epidemiology. 28: 1059-1065.

  Kiechl, S., Werner,P., Egger, G., Oberhollenzer, F., Mayr, M., Xu, Q. et al.

  2002. Active and Passive smoking, Chronic Infection, and the Risk of Carotid Atheroscelrosis.Stroke.33: 2170-2176. Koenig, W., Ernst E. 1992. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis.94: 93-107. Kofoed, S.C, Wittrup, H.H, Sillesen, H, Nordestgaard, B.G. 2003.

  Fibrinogen predicts ischemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques,The Copenhagen City Heart Study. European Heart Journal. 24:567–576. Kolominsky-Rabas, P.L., Sarti C., Heuschmann, P.U., Graf, C., Siemonsen S., Neundoerfer B., Katalinic A., Lamg E., Gessman, K.G., Von Stockert, T.R. 1998. A Prospective Community Based Study of Stroke in Germany- The Erlangen Stroke Project (ESpro) incidence and case fatality at 1,3 and 12 month. Stroke. 29: 2501 – 2506.

  Kumar, A., Sagar, R., Kumar, P., Sahu, J.K.,Grover, A., Srivastava, A.K., et al. 2013. Identification of genetic contribution to ischemic stroke by screening of single nucleotide polymorphisms in stroke patients by using a case control design. BMC Neurology.13: 136.

  Krusius T., Hirvonen M., Vahtera E., Kala R. 1994. Short-term aspirin treatment does not reduce plasma fibrinogen concentration in young healthy adults. Thrombosis Research.6: 653-656. Kwon,S., Hatzema,A.G., Duncan,P.W., Lai, S.M. 2004. Disability Measures in Stroke. Stroke.35:918:923.

  Lameshow, S, Hosmer ,D, Klar, J, Lwanga, S, 1997. Besar Sampel dalam penelitian kesehatan, Terjemahan, Yogyakarta. Gajah Mada University Press. Lam, K.S.L., Mar, O.C.K., Wat, N.M.S., Chan, L.C., Janus, E.D.1999. 

  Fibrinogen gene G/A -455 polymorphism in relation to fibrinogen levels and ischaemic heart disease in Chinese patients with Type II diabetes. Diabetologia,42: 1250-1253. Lai,S.M., Alter, M., Friday, G., Sobel. 1994. A Multifactorial Analysis of Risk Factors for Recurrence of Ischemic Stroke. Stroke. 25:958-962.

  st Lewin, B. 2000. Genes VII. 1 ed. Oxford University Press.New York.

  Levenson J, Giral P, Razavian M, Gariepy J, Simon A. 1995 Fibrinogen and Silent Atherosclerosis in Subjects With Cardiovascular Risk Factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 15:1263-68.

  Lee, S.H., Kim, M.K.,Park, M.S., Choi, S.M., Kim, J.T., Kim, B.C., Cho, K.H. 2008. Beta Fibrinogen gene -455 G/A Polymorphism in Korea Ischemic Stroke Patients. J. Clin Neurol. 4(1): 17 – 22.

  Liang,L., Sun, C., Xiao, F., Tang, X.L., Chen, X.D., Zhou, D.F., et al. 2005.

  Nine polymorphisms of fibrinogen gene and their association with plasma fibrinogen levels in Hainan Han Population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi .22 (4):457-61. Liu, Y., Saha, N., Heng, C. K., Hong, S., Low, P. S. 2001. Fibrinogen genotypes (  and ) are associated with plasma fibrinogen levels in Chinese. JMG, 38:431.

  Liu, Y., Pan, J., Wang, S., Li X., Huang,Y. 2002. Beta Fibrinogen gene

• 455 A/G polymorphism and plasma fibrinogen level in Chinese Stroke patients. Chin. Med. J ( Engl).115 : 214-216.

  Lisman,T. Weeterings,C., de Groot, P.G. 2005. Platelet aggregation: Involvement of thrombin and fibrinogen. Bioscience.10: 2504-2517. Mackie, I.J., Kitchen, S., Machin, S.J., Lowe, G.D.O. 2003. Guidelines on Fibrinogen assay. British Journal of Haematology.121:396-404. Martiskainen M., Pohjasvaara T., Mikkelsson J., Mantyla R., Kunnas T.,

  Laippala P.,et.al. 2003. Fibrinogen Gene Promoter -455 A Allele as a Risk Factor for Lacunar Stroke. Stroke,34:886-91. Martiskainen, M., Oksala, N., Pohjasvaara, T., Kaste, M, Oksala, A.,

  Karhunen, P., et.al.. 2014. Beta-Fibrinogen gene promoter A-455 allele associated with poor longterm survival among 55 – 71 years old Caucasian women in Finnish stroke cohort. BMC,14:137. Mauriello A., Sangiorgi G., Palmieri G., Virmani R., Holmes D.R. Jr.,

  Schwartz R.S. et al. 2000. Hiperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected bt transient ischemic attacks. Circulation, 101(7): 744-50.

  Meilahn, E.N., Cauley, J.A., Tracy, R.P., Macy, E.O., Gutai, J.P., Kuller, L.H. 1996. Association of sex hormone and adiposity with Plasma Levels of Fibrinogen and PAI-1 in Postmenopausal women.

  American Journal Epidemiology, 143(2): 159-166. Meschia, J.F., Brott, T.G., Brown, Jr. R.D., Cook, R.J.P., Frankel, M.,

  Hardy,J. et al. 2003. The Ischemic Stroke Genetics Study (ISGS) Protocol. BMC Neurology.3:4. Michos, E.D., Ardehali, R., Blumenthal, R.S.,Lange,R.A., Ardehali, H.

  2006. Aspirin and Clopidogrel resistence. Mayo Clin Proc.81 (4):518- 526. Milan,M., Sobrino, T., Castellanos, M., Nombela, F.Arenillas, J.F. Riva, E.

  

et al. 2007. Increased Body Iron Stores are Associated with Poor

Outcome After Thrombolytic Treatment in Acute Stroke.

  Stroke.38:90-95. Mitchell, S.V., Helmi, L.L. 2011. Genetic and inflammatory Mechanism in Stroke. Diunduh dari: www. Medscape.com/ 19/3/2013. Mirowska G.D., Gromadzka G., Mendel T., Janus L.B.,Dzierka J.,

  Sarynzka D.I. et al. 2014. Impact of BDNF 196 G/A and BDNF -270 C/T polymorphisms on stroke rehabilitation outcome: sex and age differences. Stroke Rehabil, 21: S 33-41.

  Misbach, J. 1999. Stroke: Aspek Diagnostik, Patofisiologi, Manajemen.

  Balai Penerbit FK-UI, Jakarta. Misbach, J. 2011. Stroke: Aspek diagnostik, patofisiologi, manajemen.

  Badan Penerbit FK-UI, Jakarta. Moake JL. 2002. Thrombotic Microangiopathies Mechanisms of Disease.

  N Engl J Med. 347(8):589-600. Mosesson,M.W. 2005. Fibrinogen and fibrin structure and functions.

  Journal of Thrombosis and Haemostasis.3: 1894-1904. Naito M, Funaki C, Hayashi T, Yamada K, Asai K, Yoshimine N, Kuzuya F.

  1992 Substrate-bound fibrinogen, fibrin and other cell attachment- promoting proteins as a scaffold for cultured vascular smooth muscle cells. Atherosclerosis, 96:227–34. Nan, Z., Xin, L., Yongqin, W., Xiaoqiu, L., Jiana, Li., Litian, Y. et al. 2012.

  Association of inflammatory gene polymorphisms with ischemic stroke in a Chinese Han population. Journal of Neuroinflamation, 9: 162. Nasution D, 2007. Strategi Pencegahan Stroke Primer. Pidato

  Pengukuhan Jabatan Guru Besar tetap Neurologi Fakultas Kedokteran Universitas Sumatera Utara Medan. Nedeltchev,K., Maur, T.A., Georgiadis,D., Arnold, M., Caso,V., Mattle H.P. et al. 2004. Ischemic stroke in young adults: predictors of outcome and recurrence. J. Neurol Neurosurg Psychiatry.76: 191-195. Nishiuma S., Kario K., Yakushijin K. Maeda M., Murai R., Matsuo T., et al.

  1998. Genetic Variation in the promoter region of the beta-fibrinogen gene is associated with ischemic stroke in Japanese Population.

  Blood Coagul Fibrinolysis. 9: 373-79.

  Nugroho,E.A. 2012.Farmakologi Obat-obat Penting dalam Pembelajaran Ilmu Farmasi dan Dunia Kesehatan.Pustaka Pelajar. Yogjakarata.

  Obrenovitch T.P, Urenjak J., Wang M. 2003. Nitric Oxide Formation During Cortical Spreading Depression is critical for rapid subsequent recovery of ionic homeostasis. Journal of Cerebral Blood Flow & Metabolism.22: 680-688.

  O’Donnel,M.J., Hankey, G.J., Eikelboom, J.W. 2008. Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke.

  Stroke. 39: 1638-1646. Ohira, T., Shahar,E., Chambless, L.E., Rosamond, W.D., Mosley, T.H.,

  Folsom, A.R. 2006. Risk factor for is stroke subtype: The Atherosclerosis risk in community study. 37: 2493 – 2498. Osterud, B., Bjorklid, E. 2003. Role of monocyte in atherogenesis. The American Phisiological Society. 83: 1069-1112. Patrono,C.,Andreoti, F.,Arnesen, H.,Badimon,L., Baigent, C., Collet, J.P. et al.2011. Antiplatelet agents for the Treatment and Prevention of Aterothrombosis. ( http://eurheartj.oxfordjournals.org/content/early/201 1/10/20/eurheartj.ehr373.full.pdf+html.) accessed on oktober 18, 2012. Ponrácz E, Andrikovics H, Csornai M, Bernát IS, Nagy Z, 2006,

  Fibrinogen gene and of the Leiden mutation to hemorheological parameters in ischemic stroke, Clinical Hemorheology and

  Microcirculation, 35(1-2): 75-82.

  Pohjasvaara,T., Erkinjuntti, T., Vataja, R., Kaste, M. 1997. Dementia three months After Stroke. 28: 785-792. Prasetyo, E., Harris,S., Sitorus,F., Harqutanto.2011. Waktu kedatangan pasien Stroke di Lima Rumah Sakit Pemerintah di DKI Jakarta dan

  Faktor-Faktor Yang Mempengaruhinya. Dalam: Majalah Neurona. Perhimpunan Dokter Spesialis Saraf Indonesia. Hal.15-25.

  Qizilbash N, Jones L, Warlow C, Mann J. 1991. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. BMJ ,303:605-9. Redman, C.M., Xia, H. 1999. Fibrinogen Biosynthesis Assembly, intracelullar Degradation, and Association with Lipid Synthesis and

  Secretion. Annals New York Academy of sciences. 480-495. RISKESDAS, 2008. Profil Kesehatan Indonesia. Data Penderita Stroke di Indonesia. Departemen Kesehatan Republik Indonesia. Rubattu, S., di Angelantonio, E., Nitsch, D., Gigante,B., Zanda, B. et al 2005. Polymorphisms in prothrombotic gene and their impact on ischemia stroke in Sardinian population. Thrombosis and Hemostasis.93(6): 1095-1100.

  Robbins. 2007. Aterosklerosis. Dalam: Buku Ajar Patologi. Edisi 7, Volume 2. Penerbit EGC. Jakarta:369-378. Rosenberg, R.D., Aird ,W.C. 1999. Vascular-Bed-Specific Hemostasis and Hypercoagulable States. N Engl J Med May,340(20):1555-64. Rosenson, R.S., Tangney, C.C., Mosca, L.J.1998. Hormone Replacement

  Therapy Improves Cardiovascular Risk by Lowering Plasma Viscosity in Postmenopausal Women. Arterioscler Thromb Vasc Biol. 18:1902-1905. Ross R. 1999. Atherosclerosis and inflammatory disease. N Eng J Med.

  340(2):115-26. Rothwell PM, Howard SC, Power DA. 2004 Fibrinogen Concentration and

  Risk of Ischemic Stroke and Acute Coronary Events in 5113 Patients With Transient Ischemic Attack and Minor Ischemic Stroke. Stroke. 35:2300-2305. Sacco R.L., 2000. Pathogenesis, Classification and Epidemiology of Cerebrovascular Dissease. In: Rowland L.P. ed. Merrit’s Neurology.

  1oth ed. Pp. 217 – 229. Lippincott Williams and Wilkins. Philadelphia. Sacco,R.L., Kasner,S.E., Broderick, J.P., Caplan, L.R.,Connors, J.J.,

  st

  Culebras, A. et al. 2013. An Updated Definition of Stroke for the 21 Century: A Statement for Healthcare Professionals from the American Heart Association/ American Stroke association. Stroke.

  44:2064 – 2089. Salaets K, Schliessman J, Speiser R, Tran AM, Wang E, Angerio A. 2006.

  Role of Endothelin-1 in Atherosclerosis. Goergetown Journal of Health Sciences. 3(1). Sabeti S, Exner M, Mlekusch W, Amighi J.2005. Prognostic Impact of

  Fibrinogen in Carotid Atherosclerosis Nonspecific Indicator of Inflammation or Independent Predictor of Disease Progression? Stroke. 2005;36:1400-1404.

  Saposnik,G. Del Bruto, O.H. 2003. Stroke in South Amerika: A systemic review of Incidence, Prevalence, and Stroke Subtype. Stroke. 34: 2103 – 2108.

  Sastroasmoro, S., Ismael,S .2011. Dasar-dasar Metodologi Penelitian Klinis. Edisi ke 4. Penerbit Sagung Seto. Jakarta. Sehnal, E., Slany, J. 2002. Fibrinogen the key to familial CHD or just another shadow in Plato’s Allegory?. European Heart Journal. 23:

  1231-1233. Shinohara,Y., Katayama,Y., Uchiyama,S., Yamaguchi,T., Honda,S.,

  Matsuoka,K. Et al. 2010. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomized non inferiority trial. http: www.thelancet.com/neurology, 11 september 2010.

  Sjahrir, H. 2003. Stroke Iskemik. Yandira Agung, Medan. Smith EB, Keen GA, Grant A, Stirk C. 1990. Fate of fibrinogen in human arterial intima. Arteriosclerosis.,10:263-75.

  Soekidjo, N. 2010. Metodologi Penelitian Kesehatan. Peneribit Rineka Cipta. Jakarta. Stout, R.W. , Crawford, V. 1991. Seasonal variations in fibrinogen concentrations among elderly people. Lancet. 338:9-13. Sturm, J.W., Donnan, G.A., Dewey,H.M., Macdinnell, R.A., Gilligan, A.K.

  Srikanth, V. et al. 2004. Quality of Life after Stroke: The North East Melbourne Stroke Incidence Study. Stroke. 35 : 2340-2345. Sulter, G., Steen, C. and Keyser, J.D. 1999. Use of Barthel Index and Modified Rankin Scale in Acute Stroke Trials. Stroke, 30: 1538-1541. Szmitko, P.E., Wang,C., Weisel,R.D., De Almeida,J.R., Anderson,T.J., Verma S. 2003. The role inflamation in aterosclerosis.

  Circulation.108: 1917-1923. Thrift, A.G., Dewey, H.M., Macdonell, R.A.L., Mc Neil,J.J., Donnan, G.A.

  2001. Incidence of the major Stroke subtypes : Initial finding from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke.32:1732-1738. Tsimikas, S, Bergmark,C., Beyer, R.W. 2003. Temporal increases in

  Plasma Markers of Oxidized Low- Density Lipoprotein Strongly reflect the presence of Acute Coronary Syndrome. Am. Coll. Cardiol,41: 360-370. Vane,J.R., Botting, R.M. 2003. The mechanism of action of aspirin.

  Thrombosis Research.110: 255-258. Van Oijen, M., E. Y. L. Cheung.2008.. Haplotypes of the fibrinogen gene and cerebral small vessel disease: the Rotterdam scan study." Journal of Neurology Neurosurgery and Psychiatry 79(7): 799-803. Van’t Hooft, F.M., Von Bahr, J.F., Silveira, A., Iliadon, A., Eriksson, P.,

  Hamston, A. 1999. Two Common, Functional Polymorphisms in Promoter Region of the -Fibrinogen gene contribute to Regulation to Plasma Fibrinogen concentration. Arterioscler Thromb Vasc Biol. 19: 3063-3070.

  Vierra, A.J. and Garrett, J.M. 2005. Understanding Interobserver Agreement: The Kappa Statistic. Fam Med. 37(5): 360-3. Voetsch B., Loscalzo J., 2004. Genetic Determinants of Artrial Thrombosis. Arterioscler Thromb Vasc Biol. 24: 216 – 229. Warlow C.P. 1997. Stroke a practical guide to management. 2nd ed. Great Britain: Blackwell Science Ltd. Welch, G.N., Loscalzo,J. 1998. Homocycteine and atherotmbosis. N. Eng.

  J. Med. 339(7):477. Weimar ,C., Kurth, T., Kraywinkel, K, Wagner, M., Busse, O., Haberl, R.L.,

  Dienner, H.C. 2002. Assessment of fuctioning and disability after Ischemic Stroke. Stroke.33: 2053 – 2059. Whiteley, W., Wardlaw,J., Dennis, M., Lowe, G., Rumley, A., Sattar, A., et

  

al. 2012. The Use of Blood Biomarkers to Predict Poor Outcome

  After Acute Transient Ischemic Attack or Ischemic Stroke. Stroke.43: 86-91. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L,

  Tibblin G.1984 Fibrinogen as a risk factor for stroke and Myocardial Infarction. N Engl J Med 311:501–505. Wilterdink,J.L., Bendixen,

  B., Adams, H.P., Woolson, R.F., Clarke,W.L.,Hansen, MD. 2001. Effect of Prior Aspirin use on Stroke Severity in The Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke. 32: 2836-2840.

  Woodward, M., Pedoe, H.T., Rumley,A., Lowe, G.D. 2009. Does Fibrinogen add to Prediction of cardiovascular disease? Result from the Scottish Heart Health Extended Cohort Study. Britisj Journal of Haematology.146 : 442-446.

  Wypasek E., Stepien E., Kot M., Plicner D., Kapelak B., Sadowski J. et al.

  2012. Fibrinogen Beta-Chain-C148T Polymorphism is associated with Increased Fibrinogen, C-Reactive Protein and Interleukin-6 in Patients Undergoing Coronary Artery Bypass Grafting. Inflamation, 35(2): 429-435.

  Yarnell J.w., Baker, I.A., Sweetnam P.M., Bainton D., O’Brien J.R., Whitehead P.J., et al. 1991. Fibrinogen, Viscosity, and White Blood Cell Count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies.

  Circulation, 83: 836-844. Yatsu, F.M., Villar-Cordova, C. 1998. Atherosclerosis. In: Barnett H.J.M.(editor). Stroke, Pathophysiology, diagnosis and management.

  rd 3 ed. New York. Churchill Livingstone.p. 29-37.

  Yong, M. Kaste, M. 2008. Dynamic of Hyperglicemia as A predictor of Stroke Outcome in The ECSS-Trial. Stroke. 39: 2749-2755. Zhang, Y.,Chapman, A.M.,Plested, M., Jackson D.,Purroy, F. 2012. The

  Incidence, Prevalence, and Mortality Stroke in France, Germany, Italia, Spain, the UK, and the USA: A Literature Review. Stroke Research and Treatment: 1-11.